In 1991 Dr. Nikolaus Grubhofer started research to make his vision come true. He had decided to develop a better adjuvant with the goals: match Freund's adjuvant as the yardstick of efficiency, make it perfectly biotolerable, remove the emulsion handling problem, maintain a reasonable price level and get it patented and licensed. Many formulations and data have become available as the result of the 50 years of scientific work following Freund. The trouble with all this work was that it was done nearly exclusively with mice and was of very limited use with larger animals, which were the necessary models for veterinary and human vaccination.
In 2001 the GERBU Adjuvant (GAD) formulations basically were ready: A microsuspension of cationized lipid solid particles in water combined with GMDP and other synergists. They could be simply mixed with the antigen solution and were as effective as Freund's FCA, also in other species such as sheep, goats, cattle and humans - but devoid of its drawbacks: They were completely biocompatible and easy to use, suitable for a wide range of applications and potentially for licensing in pharmaceutical use.
Our formulations are still being investigated and optimized to the latest scientific findings. More than 30 years of development and field tests, GAD have emerged as the most efficient, biocompatible, convenient and economical successors of adjuvants as Freund's.
GERBU ADJUVANTS - powerful potentiators of cellular and humoral immune response with long-term protecting effect. Very stable and biocompatible. Just mix with antigen - inject.